Zacks Investment Research Lowers Tarsus Pharmaceuticals (NASDAQ:TARS) to Sell


Share on StockTwits

Zacks Investment Research cut shares of Tarsus Pharmaceuticals (NASDAQ:TARS) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company’s product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. “

NASDAQ TARS opened at $27.86 on Wednesday. The firm has a 50 day moving average price of $33.32. Tarsus Pharmaceuticals has a 1-year low of $15.32 and a 1-year high of $63.69.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Citigroup Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $48,000. Wells Fargo & Company MN purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $132,000. New York State Common Retirement Fund acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $145,000. American International Group Inc. acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $148,000. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $355,000.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Article: Treasury Bonds

Get a free copy of the Zacks research report on Tarsus Pharmaceuticals (TARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.